Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms.
Oxidized low density lipoprotein (oxLDL) induces apoptosis in vascular cells. To elucidate the mechanisms involved in this apoptosis, we studied the apoptosis-inducing activity in lipid fractions of oxLDL and the roles of two common mechanisms, ceramide generation and the activation of caspases, in apoptosis in human umbilical vein endothelial cells treated with oxLDL. We also studied the effects of antioxidants and cholesterol. oxLDL induced endothelial apoptosis in a time- and dose-dependent fashion. Apoptosis-inducing activity was recovered in the neutral lipid fraction of oxLDL. Various oxysterols in this fraction induced endothelial apoptosis. Neither the phospholipid fraction nor its component lysophosphatidylcholine induced apoptosis. oxLDL induced ceramide accumulation temporarily at 15 min in a dose-dependent fashion. Two inhibitors of acid sphinogomyelinase inhibited both the increase in ceramide and the apoptosis induced by oxLDL. Furthermore, a membrane-permeable ceramide (C2-ceramide) induced endothelial apoptosis. These findings demonstrated that ceramide generation by acid sphingomyelinase is indispensable for the endothelial apoptosis induced by oxLDL. Inhibitors of both caspase-1 and caspase-3 inhibited the apoptosis, suggesting that oxLDL induced apoptosis by activating these cysteine proteases. The antioxidants butylated hydroxytoluene and superoxide dismutase but not catalase inhibited the apoptosis induced by oxLDL or 25-hydroxycholesterol. This suggests not only that superoxide plays an important role but also that a critical interaction between oxLDL and the cell takes place on the outer surface of the membrane, because superoxide dismutase is not membrane-permeable. Exogenous cholesterol also inhibited the apoptosis. Our study demonstrated that neutral lipids in oxLDL induce endothelial apoptosis by activating membrane sphingomyelinase in a superoxide-dependent manner, as well as by activating caspases.
Harada-Shiba
M
M
National Cardiovascular Center Research Institute, 7-1 Fujishirodai 5-chome, Suita, Osaka 565-8565, Japan.
Kinoshita
M
M
Kamido
H
H
Shimokado
K
K
D000975:Antioxidants / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D002084:Butylated Hydroxytoluene / Q000494:pharmacology; D002374:Catalase / Q000494:pharmacology; D002478:Cells, Cultured; D002518:Ceramides / Q000378:metabolism; D002784:Cholesterol / Q000031:analogs & derivatives / Q000494:pharmacology*; D003546:Cysteine Endopeptidases / Q000096:biosynthesis; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D004789:Enzyme Activation; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008077:Lipoproteins, LDL / Q000494:pharmacology*; D010084:Oxidation-Reduction; D013110:Sphingosine / Q000031:analogs & derivatives / Q000494:pharmacology; D013261:Sterols / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000494:pharmacology; D014471:Umbilical Veins
D000975:Antioxidants; D002518:Ceramides; D015853:Cysteine Proteinase Inhibitors; D008077:Lipoproteins, LDL; C064769:N-acetylsphingosine; D013261:Sterols; C099252:oxidized low density lipoprotein; D016222:Fibroblast Growth Factor 2; D002084:Butylated Hydroxytoluene; D002784:Cholesterol; D002374:Catalase; D013482:Superoxide Dismutase; D003546:Cysteine Endopeptidases; D013110:Sphingosine